Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 456 participants.

Also called NCT01951625

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 456 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01951625
  • EudraCT 2013-002287-11
Main results
  • Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial JAMA, 2015-12-01 DOI, PubMed 26547357

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, Poland, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01951625. Randomized; quadruple masking; primary purpose treatment. Start 2013-11-29 (actual); primary completion 2015-05-14 (actual). Results posted on 2021-03-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Condition
Heart Failure
Intervention (Drug)
Vericiguat (BAY1021189) (1.25 mg)
Intervention (Drug)
Vericiguat (BAY1021189) (5 mg)
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01951625
Content hash
794513dbadb1c49cc741c512d2f203e16b5ec1fde582ed4b914cbb0828d48935